Manoussos Perros
Chief Executive Officer chez ENTASIS THERAPEUTICS HOLDINGS INC.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Nicholas G. Galakatos | M | 66 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 ans |
| Mike Gutch | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Entasis Therapeutics Ltd.
 Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The private company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | 7 ans |
| Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 ans |
| David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 ans |
| James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 ans |
| Heather Elizabeth Preston | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 ans |
| Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 ans |
| David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 ans |
| Ruben Tommasi | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 13 ans |
| John Mueller | M | 64 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 13 ans |
| Richard Levin | M | 77 |
Yale University
| 31 ans |
| David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 ans |
| Kyle Dow | M | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Pavel Raifeld | M | 40 | 2 ans | |
| Anna Diaz Triola | F | - | 3 ans | |
| Marianne Zhen | F | 55 | 2 ans | |
| Louise M. Dembry | M | - |
Yale University
| 31 ans |
| Elan Gandsman | M | 82 |
Yale University
| 31 ans |
| Matthew Ronsheim | M | 52 | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Gregory Norden | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Simon Lowth | M | 62 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | - |
| Eric W. Kimble | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 1 ans |
| Xu Hui Shen | M | 45 |
Yale University
| 6 ans |
| Sarah P. Payne | F | - |
Yale University
| 4 ans |
| Howard Mayer | M | 62 | 3 ans | |
| Bing Yuan | M | 55 |
Yale University
| 5 ans |
| Anders Olof Adolf Ekblom | M | 70 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 7 ans |
| Shakil Waiz Ahmed | M | - |
Yale University
| 6 ans |
| Robert Hopfner | M | 51 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Gao Wang | M | 59 |
Yale University
| 5 ans |
| Joseph Patt | M | - |
Yale University
| 4 ans |
| Blaise A Coleman | M | 50 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 4 ans |
| Swan Chang | M | - |
Yale University
| 4 ans |
| Thomas Dyrberg | M | 69 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| So-Young Kim | M | 57 |
Yale University
| 3 ans |
| Josh Duhl | M | - |
Yale University
| 5 ans |
| Kristie Wagner | F | 57 | - | |
| Felton Jenkins | M | - |
Yale University
| 3 ans |
| Ophir Klein | M | - |
Yale University
| 7 ans |
| Robin Isaacs | M | 65 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 4 ans |
| Linda Lorimer | F | 72 |
Yale University
| - |
| Jaime R. Harrison | M | - |
Yale University
| 4 ans |
| Daniel Joseph Duggan | M | - |
Yale University
| 4 ans |
| Tom Newell | M | - |
Yale University
| 4 ans |
| Aamer Abdullah | M | - |
Yale University
| 4 ans |
| Dwight S. Yoo | M | - |
Yale University
| 4 ans |
| Jack Taylor Thompson | M | 52 |
Yale University
| 4 ans |
| Nell Breyer | F | - |
Yale University
| 4 ans |
| Carrie Mermelstein | F | - |
Yale University
| 4 ans |
| Simon Duxbury | M | - |
Yale University
| 4 ans |
| Gang-Shik Choi | M | 64 |
Yale University
| 3 ans |
| Zachary Krug | M | - |
Yale University
| 4 ans |
| Zach Scheiner | M | 47 |
Yale University
| 4 ans |
| Ke Wei Xie | M | 63 |
Yale University
| 3 ans |
| Kenneth Toshima | M | - |
Yale University
| 2 ans |
| Colin Savage | M | - |
Yale University
| 4 ans |
| Anthony Philippakis | M | 48 |
Yale University
| 4 ans |
| Quentin Koffey | M | - |
Yale University
| 4 ans |
| Nithyanantham Gunananthan | M | 56 |
Yale University
| 1 ans |
| Brent Irvin | M | 52 |
Yale University
| 1 ans |
| Yukie Nakano | M | 59 |
Yale University
| 3 ans |
| Erin Lavelle | F | 46 |
Yale University
| 3 ans |
| Nathan R. Harrington | M | 57 |
Yale University
| 2 ans |
| Frank Fabozzi | M | 76 |
Yale University
| 17 ans |
| Hironori Kamemoto | M | - |
Yale University
| 3 ans |
| Robert Kinderman | M | 48 |
Yale University
| 4 ans |
| Damon S. Judd | M | - |
Yale University
| 4 ans |
| Xiao-Hong Jing | F | - |
Yale University
| 3 ans |
| John Ellertson Peetz | M | - |
Yale University
| 4 ans |
| Bengt Robert Holmström | M | 75 |
Yale University
| 9 ans |
| Andy Toburen | M | 52 |
Yale University
| 4 ans |
| Martin Hale | M | 52 |
Yale University
| 4 ans |
| Greg Bond | M | 53 |
Yale University
| 4 ans |
| Yogesh Vishnu Borkar | M | - |
Yale University
| 2 ans |
| Kent E. Radspinner | M | - |
Yale University
| 2 ans |
| David Stephen Charney | M | - |
Yale University
| 4 ans |
| Ryan A. Rauch | M | - |
Yale University
| 4 ans |
| Brian Charles Osias | M | - |
Yale University
| 4 ans |
| Rich Edelman | M | - |
Yale University
| 4 ans |
| Nicholas G. Demmo | M | - |
Yale University
| 4 ans |
| Umut Ergun | M | - |
Yale University
| 4 ans |
| Corby Reese | M | - |
Yale University
| 10 ans |
| Shail Khiyara | M | 57 |
Yale University
| 2 ans |
| Charles Lazor | M | - |
Yale University
| 1 ans |
| Zheng Ma | M | 57 |
Yale University
| 3 ans |
| Jon Levinson | M | - |
Yale University
| 4 ans |
| Massimiliano Marzo | M | - |
Yale University
| 2 ans |
| Ingrid Kiefer | F | - |
Yale University
| 5 ans |
| John V. Calce | M | - |
Yale University
| 4 ans |
| Emily Rabin Cowan | F | - |
Yale University
| 4 ans |
| Pawel Chudzicki | M | - |
Yale University
| 4 ans |
| Peter Beinart | M | - |
Yale University
| 4 ans |
| Xiang Liu | M | - |
Yale University
| 3 ans |
| Seth Seifman | M | - |
Yale University
| 4 ans |
| Tarun M. Stewart | M | - |
Yale University
| 3 ans |
| Jay Michaelson | M | - |
Yale University
| 3 ans |
| Jerry B. Pence | M | - |
Yale University
| 4 ans |
| David Ira Schamis | M | 50 |
Yale University
| 4 ans |
| steve kraus | M | - |
Yale University
| 4 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 96 | 96,97% |
| Suède | 5 | 5,05% |
| Royaume-Uni | 1 | 1,01% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Manoussos Perros
- Réseau Personnel
